A new market study, titled “Discover Global Atrial Fibrillation Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.
Atrial Fibrillation is an irregular or rapid heartbeat that can lead to heart failure, blood clots, stroke, and other heart-related diseases. When a heart function normally it contracts and relaxes to a regular heartbeat but in the case of Atrial Fibrillation the atria beats irregularly and goes out of coordination with the two lower chambers. A stroke results when a clot breaks off and enters the bloodstream, lodges into an artery leading to the brain. Atrial Fibrillation patients are kept on a blood thinner to avoid this condition.
Atrial Fibrillation itself is not life-threatening but it may lead to life-threatening diseases if it remains undiagnosed or untreated. The early diagnosis of the disease can help to control the consequences. The main problem with Atrial Fibrillation is the clotting of the blood within the upper chambers or atria. These blood clots may circulate and lead to a blocked blood clot in other organs. A wide range of treatments is available to treat Atrial Fibrillation. The treatment may alter the heart’s electrical system.
Atrial Fibrillation symptoms are a weakness, fatigue, dizziness, shortness of breath, palpitations, chest pain, etc. To restore a normal heartbeat, medication and other effective treatments are essential to lead a normal life. There is a rising number of cases of Atrial Fibrillation among the aging and geriatric population. There is a drastic increase in Atrial Fibrillation due to lifestyle disorders which may lead to complicated conditions. The market of Atrial Fibrillation is growing at a fast pace owing to the increase in awareness towards the disease and government initiative to keep the disease in control.
Get Free Sample Report at https://www.wiseguyreports.com/sample-request/3791994-global-atrial-fibrillation-market-2019-2026
Key Players of Global Atrial Fibrillation Market =>
Abbott Laboratories, Johnson & Johnson, Boston Scientific Corporation, Medtronic plc, Biotronik SE & Co. KG, Koninklijke Philips N.V., Siemens AG, GE Healthcare, Boehringer Ingelheim, Sanofi, Baxter, Bristol-Myers Squibb and Pfizer
By type, the global Atrial Fibrillation market in the section – Medication, Surgical Procedures, and Non-Surgical Procedure. By medication type, the global Atrial Fibrillation market in the section – Heart Rate Controlling Medication, Anti-Clotting Medication, and Heart Rhythm Controlling Medication. By anti-clotting medication type, the global Atrial Fibrillation market in the section – Antiplatelets and Anticoagulants. By heart rate-controlling medication type, the global Atrial Fibrillation market in the section – Calcium Channel Blockers, Beta Blockers, and Digoxin. By surgical procedure type, the global Atrial Fibrillation market in the section – Pacemakers and Open-Heart Maze Procedure. By non-surgical procedures type, the global Atrial Fibrillation market in the section – Electrical Cardioversion and Ablation. By ablation type, the global Atrial Fibrillation market in the section – Radiofrequency Ablation or Catheter Ablation. By application, the global Atrial Fibrillation market in the section – Electrophysiology Labs, Hospitals, and Ambulatory Surgical Center.
Europe and North America’s Atrial Fibrillation market achieve growth with the growing number of people suffering with it. The increase in the number of geriatric population leads to the growing number of patients suffering from Atrial Fibrillation. The growing number of patients with Atrial Fibrillation is also due to the unhealthy lifestyle that leads to hypertension, obesity, and diabetes. South America’s Atrial Fibrillation market achieves growth due to the increase in the aging population. Aging people are more prone to Atrial Fibrillation. With the development of medical diagnosis and treatment, the market of Atrial Fibrillation will grow rapidly. Asia-Pacific (APAC) Atrial Fibrillation market to achieve growth due to the growing awareness of the disease.
November 11, 2019. A study conducted by a team of scientists concluded that electrocardiograms can predict the outcome of the disease in patients who may likely develop an irregular heartbeat. It was found that Artificial Intelligence was able to predict the patients who can be at higher risk. The studies will be presented at the American Heart Association Scientific Sessions 2019 which will be conducted by Geisinger researchers.
Get Detailed Report at https://www.wiseguyreports.com/reports/3791994-global-atrial-fibrillation-market-2019-2026
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)